Skip to main content
Multiple Sclerosis Discovery Forum
Inspiring Connections
Utility Navigation
Feedback
Newsletter
RSS
Twitter
User Top Menu
Welcome, guest
Log In
Join
Why Join?
Search form
Search
About Us
Overview
Who We Are
Contact
Fan Mail
How to Cite
News & Future Directions
New Findings
News Briefs
Podcasts
News Synthesis
Essays & Opinions
Blogs
Papers
Editors' Picks
Classic Papers
Archive
Forums
Discussions
Webinars
Professional Resources
Meetings & Events
Past Meetings
Funding Opportunities
Jobs
Member Directory
Bulletin Board
Useful Links
Research Resources
Data Visualizations
Clinical Trials - Public Availability of Results
World Map
MS trials baseline
NMO History
NMO Galaxy
Map of MS Prevalence
Progressive MS Authors Galaxy
Word Cloud
MSLine
Ongoing Clinical Trials in MS
MRI-Related Clinical Trials
RRMS and CIS
Immunopathogenesis of MS
The MS Galaxy
ARR in Placebo Groups
Symptoms Prevalence
Scientific Literature TreeMap
Clinical Trials in MS
Drug-Development Pipeline
Tissue Repositories
MSGene
Animal Models
Clinical Trials
Click Here to Support MSDF
You are here
Home
Most Viewed
The Effect of Fingolimod on Conversion of Acute Gadolinium-Enhancing Lesions to Chronic T1 Hypointensities in Multiple Sclerosis.
Histone Deacetylase (HDAC) Inhibitors - emerging roles in neuronal memory, learning, synaptic plasticity and neural regeneration.
Microglia and their CX3CR1 signaling are involved in hippocampal- but not olfactory bulb-related memory and neurogenesis.
Multiple sclerosis eye-brain dynamic correlation.
Macrophages in inflammatory multiple sclerosis lesions have an intermediate activation status.
Clinical predictors of an optimal response to natalizumab in multiple sclerosis.
Assessing spinal cord function in multiple sclerosis with functional neuroimaging: insights and limitations.
High risk of cardiovascular diseases after diagnosis of multiple sclerosis.
Vitamin D and multiple sclerosis: timing of sampling, treatment and prevention.
Decreased serum levels of nucleolin protein fragment, as analyzed by bead-based proteomic technology, in multiple sclerosis patients compared to controls.
Mixed Panniculitis Secondary to Interferon beta-1a Therapy in a Woman With Multiple Sclerosis.
A Potent and Selective S1P(1) Antagonist with Efficacy in Experimental Autoimmune Encephalomyelitis.
MS risk genes are transcriptionally regulated in CSF leukocytes at relapse.
Differential Cerebellar Functional Interactions during an Interference Task across Multiple Sclerosis Phenotypes.
Progressive multiple sclerosis exhibits decreasing glutamate and glutamine over two years.
Comparison of Disease Activity in SPMS and PPMS in the Context of Multicenter Clinical Trials.
Treg cell resistance to apoptosis in DNA vaccination for experimental autoimmune encephalomyelitis treatment.
An Overview of Models, Methods, and Reagents Developed for Translational Autoimmunity Research in the Common Marmoset (Callithrix jacchus).
Clostridia as agents of zoonotic disease.
2014 multiple sclerosis therapeutic update.
Role of Chlamydia in Multiple Sclerosis.
Disseminated cryptococcosis in a patient with multiple sclerosis treated with fingolimod.
Glatiramer acetate for treatment of relapsing-remitting multiple sclerosis.
Type I interferons as ambiguous modulators of chronic inflammation in the central nervous system.
Fornix as an imaging marker for episodic memory deficits in healthy aging and in various neurological disorders.
Pages
« first
‹ previous
…
288
289
290
291
292
293
294
295
296
…
next ›
last »